{"extraction_ratio": 0.89, "to_compare": [{"generated": ["progressive mobilization", "complete normalization"], "gold": []}, {"generated": ["fourth course"], "gold": []}, {"generated": ["May 2009"], "gold": []}, {"generated": ["16"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["increased number and types of chemotherapeutic drugs", "prolonged life expectancy"], "gold": []}, {"generated": ["patient"], "gold": []}, {"generated": ["health risks", "complexity"], "gold": []}, {"generated": ["chronic back pain"], "gold": []}, {"generated": ["low dopamine concentrations", "movement control"], "gold": []}, {"generated": ["pharmacogenomic", "pharmacokinetic", "pharmacodynamic"], "gold": []}, {"generated": ["chronic neck, back, and shoulder pain", "past medical history"], "gold": []}, {"generated": ["early in the morning"], "gold": []}, {"generated": ["additional medication"], "gold": []}, {"generated": ["numerous ages found in text"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["patient\u2019s PGx results (Table 1)", "genotype for COMT Met/Met"], "gold": []}, {"generated": ["one out of five"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["past two decades"], "gold": []}, {"generated": ["2009-2010"], "gold": []}, {"generated": ["South Korean population", "29%", "83%"], "gold": []}, {"generated": ["very narrow therapeutic indices"], "gold": []}, {"generated": ["an increasing number of studies"], "gold": []}, {"generated": ["important", "clinic", "studies"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rs1142345"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["last decade"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["about 70%"], "gold": []}, {"generated": ["CYP2C9", "CYP2C19", "CYP1A2", "potential interaction"], "gold": []}, {"generated": ["K A", "time course", "non-targeted approach", "metabolites"], "gold": []}, {"generated": ["intestinal absorption", "bioavailable concentration", "plasma concentration", "weight extracted powdered material", "weight of original starting material", "bioavailability"], "gold": []}, {"generated": ["public interest", "tremendous surge"], "gold": []}, {"generated": ["chronically"], "gold": []}, {"generated": ["indigenous mode of extraction"], "gold": []}, {"generated": ["44"], "gold": []}, {"generated": ["Waters micromass", "column oven", "UPLC system", "binary pump", "autosampler", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "Acquity BEH C18 column", "serial dilutions", "vacuum degasser", "mixture of regeneration system"], "gold": []}, {"generated": ["almost all"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["clinical pharmacokinetic profile", "vivo"], "gold": []}, {"generated": ["increasing"], "gold": []}, {"generated": ["31%"], "gold": []}, {"generated": ["96 h after dose", "1, 20, 6, 14%", "1985"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["day before", "2 days after"], "gold": []}, {"generated": ["2003"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["1 : 80", "1 : 40"], "gold": []}, {"generated": ["chronic hepatitis", "moderate plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "mild cholangiolar proliferation"], "gold": []}, {"generated": ["Tables 1, 2, and 3", "clinicopathological features", "Case 1"], "gold": []}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "fatigue", "initially asymptomatic"], "gold": []}, {"generated": ["vasomotor symptoms of menopause"], "gold": []}, {"generated": ["discontinuation of the herbal supplement"], "gold": []}, {"generated": ["drug", "immunogen", "metabolite", "hapten", "autoimmune response", "host cellular protein", "immune mechanism"], "gold": []}, {"generated": ["Adults"], "gold": []}, {"generated": ["differences", "black cohosh hepatotoxicity", "similarities", "published cases", "case studies"], "gold": []}, {"generated": ["third-generation fluoroquinolone antibiotic family"], "gold": []}, {"generated": ["urinary system infection"], "gold": []}, {"generated": ["pharmacokinetic features", "in vivo distribution studies"], "gold": []}, {"generated": ["rat tissue homogenate"], "gold": []}, {"generated": ["42 mg kg"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u00b115%", "acceptable limit"], "gold": []}, {"generated": ["distribution rate in the tissue", "entrance of LVFX"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pharmacodynamic interactions", "pharmacokinetic interactions"], "gold": []}, {"generated": ["2017"], "gold": []}, {"generated": ["people with diabetes"], "gold": []}, {"generated": ["anti-inflammatory", "anticancer", "anti-osteoporosis", "antioxidant"], "gold": []}, {"generated": ["Trypsin EDTA", "Hanks balanced salt solution (HBSS)", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Penicillin-streptomycin", "HEPES"], "gold": []}, {"generated": ["No ages found in text"], "gold": []}, {"generated": ["2011"], "gold": []}, {"generated": ["2006"], "gold": []}, {"generated": ["P < 0.001", "P < 0.05", "P < 0.01"], "gold": []}, {"generated": ["hypocholesterolemic drugs", "hypoglycemic drugs"], "gold": []}, {"generated": ["global increase in the prevalence of diabetes and obesity"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP2C9", "CYP2C8", "CYP3A4"], "gold": []}, {"generated": ["DMSO", "acetonitrile", "methanol"], "gold": []}, {"generated": ["30 min"], "gold": []}, {"generated": ["15%\u201320%"], "gold": []}, {"generated": ["10 mg/mL"], "gold": []}, {"generated": ["positive CYP2C9 inhibitor", "positive CYP2C8 inhibitor", "positive CYP3A4 inhibitor"], "gold": []}, {"generated": ["in vitro", "CYP3A4", "drugs metabolized by CYP2C8"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["well tolerated", "all participants"], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["eight"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Subsequently"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["docetaxel AUC0\u2013\u221e"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["midazolam studies"], "gold": []}, {"generated": ["leaves", "different parts of E. purpurea plants", "roots"], "gold": []}, {"generated": ["gene reporter assay", "LS180 cells", "E. purpurea extracts", "alkylamides", "CYP3A4 induction potential"], "gold": []}, {"generated": ["pharmacokinetics of docetaxel"], "gold": []}, {"generated": ["cancer patients"], "gold": []}, {"generated": ["advanced cancer"], "gold": []}, {"generated": ["product dependent"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["10 \u00b5L ethyl gallate", "100 \u00b5L plasma"], "gold": []}, {"generated": ["139.00", "443.10", "291.20", "199.00", "151.00", "127.03", "123.00", "307.20"], "gold": []}, {"generated": ["EGC", "ECG", "50 ng/mL", "500 ng/mL", "EGCG", "0.1", "EC"], "gold": []}, {"generated": ["200 \u00b5L"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Sixteen"], "gold": []}, {"generated": ["mild", "adults", "no specific age mentioned", "adolescents", "children"], "gold": []}, {"generated": ["Day 15", "Day 1"], "gold": []}, {"generated": ["AUC", "Day 1", "digoxin alone treatment"], "gold": []}, {"generated": ["study", "reduced", "systemic exposure"], "gold": []}, {"generated": ["ratios", "mean \u00b1 SD", "start of the study"], "gold": []}, {"generated": ["repeated administration group", "control group"], "gold": []}, {"generated": ["rats", "RGE", "ginsenosides", "plasma concentrations", "1 or 2 weeks"], "gold": []}, {"generated": ["rats"], "gold": []}, {"generated": ["rat plasma"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rheumatoid arthritis"], "gold": []}, {"generated": ["rheumatoid arthritis"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["Seoul, Korea"], "gold": []}, {"generated": ["100 mg", "liver samples"], "gold": []}, {"generated": ["2 h"], "gold": []}, {"generated": ["Red ginseng extract"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["RGE"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["2014"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["3.5 \u03bcm"], "gold": []}, {"generated": ["-40", "10", "3500"], "gold": []}, {"generated": ["Rat liver microsomes"], "gold": []}, {"generated": ["half-life"], "gold": []}, {"generated": ["highest recovery"], "gold": []}, {"generated": ["six different rats"], "gold": []}, {"generated": ["1", "500", "ng/mL"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["large individual differences"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["combinations", "reports", "studies"], "gold": []}, {"generated": ["neonates", "patients with renal dysfunction"], "gold": []}, {"generated": ["our analysis of the literature"], "gold": []}, {"generated": ["experimental rats", "control rats"], "gold": []}, {"generated": ["Experiments in mice"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["rats", "digoxin-induced arrhythmias"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["limited research"], "gold": []}, {"generated": ["complex"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["potential for herb-drug interactions"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["systemic levels", "two or more drugs"], "gold": []}, {"generated": ["none"], "gold": []}, {"generated": ["proper drug disposition"], "gold": []}, {"generated": ["C. asiatica"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0.1% (v/v)"], "gold": []}, {"generated": ["ambient temperature"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["means \u00b1 S.D."], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Prism 8.0.2"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["standard deviation (S.D.)", "mean"], "gold": []}, {"generated": ["standard deviation (S.D.)", "mean"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["data not shown"], "gold": []}, {"generated": ["2002", "2011", "2012", "1996", "2017", "2006", "2003", "3"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["triplicate"], "gold": []}, {"generated": ["human P450 forms", "CYP2C9", "CYP2D6", "CYP2C19", "human liver microsomes", "CYP3A4"], "gold": []}, {"generated": ["plasma concentrations", "clinical studies", "CAW-R61J"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["phase II"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["chronic kidney disease"], "gold": []}, {"generated": ["Each sample"], "gold": []}, {"generated": ["high concentrations", "medium concentrations", "low concentrations"], "gold": []}, {"generated": ["berberine (IS)", "150 \u03bcL", "1 ng/mL"], "gold": []}, {"generated": ["24 h", "6 \u00b0C"], "gold": []}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": []}, {"generated": ["jejunal segments"], "gold": []}, {"generated": ["50 \u03bcL", "150 \u03bcL", "1 ng/mL"], "gold": []}, {"generated": ["product ion scan results", "authentic standards", "previously published reports"], "gold": []}, {"generated": ["rat plasma samples", "1 h after"], "gold": []}, {"generated": ["85", "115"], "gold": []}, {"generated": ["hypertension"], "gold": []}, {"generated": ["ages", "mass fragmentation patterns", "product ion mass spectra", "adults", "reported"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CV", "mean", "experiments"], "gold": []}, {"generated": ["chronic"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["developing countries"], "gold": []}, {"generated": ["most diseases"], "gold": []}, {"generated": ["26"], "gold": []}, {"generated": ["intestinal absorption", "bioavailable concentration", "test compound", "GI tract", "plasma concentrations", "soluble extract"], "gold": []}, {"generated": ["mg\u00b7kg"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["concentration-dependent inhibition"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["72 h", "24 h"], "gold": []}, {"generated": ["Michelle Skelton", "Ambroise Wonkam", "Dee Blackhurst", "Kevin Dzobo", "Denis Chopera"], "gold": []}, {"generated": ["final manuscript"], "gold": []}, {"generated": ["five major ingredients"], "gold": []}, {"generated": ["three treatments", "7 \u00b1 1-day washout period"], "gold": []}, {"generated": ["our study"], "gold": []}, {"generated": ["1000 mg \u00d7 4 times", "1000 mg", "8 tablets"], "gold": []}, {"generated": ["1000 mg \u00d7 4 times daily", "1000 mg once daily"], "gold": []}, {"generated": ["7680 mg", "1000 mg"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pharmacokinetic (PK) parameters"], "gold": []}, {"generated": ["elderly subjects"], "gold": []}, {"generated": ["greater than 65 years of age"], "gold": ["greater than 65 years of age"]}, {"generated": ["elderly"], "gold": []}, {"generated": ["five days"], "gold": []}, {"generated": ["ultraviolet absorption spectra", "retention times"], "gold": []}, {"generated": ["45"], "gold": []}, {"generated": ["presupplementation", "postsupplementation"], "gold": []}, {"generated": ["17"], "gold": []}, {"generated": ["young individuals"], "gold": []}, {"generated": ["54"], "gold": []}, {"generated": ["42"], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["various ages found in text"], "gold": []}, {"generated": ["18"], "gold": []}, {"generated": ["specific CYP isoforms", "little effect"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["conventional medications"], "gold": []}, {"generated": ["HPLC method", "3-hydroxyquinine", "plasma quinine"], "gold": []}, {"generated": ["6", "8", "11", "10", "9", "7"], "gold": []}, {"generated": ["breastfeeding", "histories of hypersensitivity to quinine or similar agents", "adverse side effects from taking G. kola seeds", "pregnancy"], "gold": []}, {"generated": ["certified healthy", "written informed consent"], "gold": []}, {"generated": ["600 mg quinine sulphate tablets", "overnight fast"], "gold": []}, {"generated": ["1, 2, 3, 4, 6, 8, 12, 24, 36, 48 h"], "gold": []}, {"generated": ["0.37\u00b5g/ml", "0.5\u00b5g/ml"], "gold": []}, {"generated": ["0\u2013\u221e"], "gold": []}, {"generated": ["very light dizziness"], "gold": []}, {"generated": ["38"], "gold": []}, {"generated": ["T1/2", "CL/F"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["77"], "gold": []}, {"generated": ["KwaZulu-Natal", "adults", "worldwide"], "gold": []}, {"generated": ["1200 mg"], "gold": []}, {"generated": ["both arms", "serial electrocardiograms", "PR interval", "corrected QT interval (QTc)", "QRS duration"], "gold": []}, {"generated": ["ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["data", "occurrence", "prevalence", "percent"], "gold": []}, {"generated": ["increasing incidence", "chronic kidney disease (CKD)"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["patients' age"], "gold": []}, {"generated": ["20\u201360 years"], "gold": ["20\u201360 years"]}, {"generated": ["13.23%"], "gold": []}, {"generated": ["50\u201370 years"], "gold": ["50\u201370 years"]}, {"generated": ["middle-aged (50\u201364)"], "gold": ["50\u201364"]}, {"generated": [], "gold": []}, {"generated": ["27"], "gold": []}, {"generated": ["90%"], "gold": []}, {"generated": ["2 months", "18 F"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["6 min", "0.5 mL"], "gold": []}, {"generated": ["each blood sampling time"], "gold": []}, {"generated": ["known factor activity", "standard human plasma", "clotting time"], "gold": []}, {"generated": ["apparent volume of distribution (V/F)", "dose", "ln 2/kel", "CL/kel", "half-life", "apparent clearance (CL/F)", "AUC0-\u221e"], "gold": []}, {"generated": ["percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "two-compartment pharmacokinetic model", "INR data"], "gold": []}, {"generated": ["data not shown"], "gold": []}, {"generated": ["0.94 (0.67\u20131.47)", "60.3 (54.5\u201366.1)", "1.06 (0.83\u20131.19)", "0.010 (0.007\u20130.013)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "NA", "65.5 (55.3\u201375.6)", "1.4 (1.1\u20131.6)", "1.06 (0.95\u20131.19)", "1.9 (1.5\u20132.2)", "63.0 (57.3\u201368.8)", "1.9 (1.1\u20132.7)", "0.010 (0.007\u20130.014)", "1.12 (0.39\u20131.84)", "1.04 (0.94\u20131.67)", "1.3 (1.1\u20131.6)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2007"], "gold": []}, {"generated": ["7 patients"], "gold": []}, {"generated": ["2007"], "gold": []}, {"generated": ["patients", "common", "adults"], "gold": []}, {"generated": ["information websites", "popular publications", "directed to cancer patients", "recent"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["600 mg"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["conclusions", "data", "results", "studies"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["36"], "gold": []}, {"generated": ["14 subsequent days"], "gold": []}, {"generated": ["1-hydroxymidazolam/midazolam serum ratio", "debrisoquine urinary recovery ratio", "hydroxychlorzoxazone/chlorzoxazone serum ratio", "paraxanthine/caffeine serum ratio"], "gold": []}, {"generated": ["12 weeks", "15 days"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["two case reports"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["essential", "clinical risks"], "gold": []}, {"generated": ["in vitro", "in vivo"], "gold": []}, {"generated": ["relevant risk", "valid clinical observations"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP-isoenzymes", "UGT", "P-gp"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["7 days"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["normalization of the LVEF", "regression of the radiological abnormalities", "rapid improvement"], "gold": []}, {"generated": ["drug-induced cardiopulmonary toxicity"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["probably associated with venlafaxine"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["circunstancial", "metaboliza\u00e7\u00e3o lenta"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["maioria"], "gold": []}, {"generated": ["35 anos de idade"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["menopausal symptoms"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["result of adverse reaction", "degree of adverse reaction", "date of onset", "date of disappearance"], "gold": []}, {"generated": ["statistically significant difference", "ages", "demographic information"], "gold": []}, {"generated": ["p-value", "Fisher's exact test"], "gold": []}, {"generated": ["fully recovered"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["large-scale", "long period"], "gold": []}, {"generated": ["UGT2B7", "UGT1A1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Lineweaver-Burk plots", "Dixon", "second quadrant", "intersection", "vertical axis"], "gold": []}, {"generated": ["0.49 \u03bcM"], "gold": []}, {"generated": ["120-fold", "13-fold"], "gold": []}, {"generated": ["many drugs"], "gold": []}, {"generated": ["previous"], "gold": []}, {"generated": ["AGE: Not specified"], "gold": []}, {"generated": ["chronic liver disease"], "gold": []}, {"generated": ["0.5\u20132.0 g/kg"], "gold": []}, {"generated": ["rats", "human"], "gold": []}, {"generated": ["RGE", "repeated administration", "high dose", "valsartan", "Rc"], "gold": []}, {"generated": ["7.8 \u03bcM", "0.4\u20130.5%", "0.1\u20130.2%", "34.1 \u03bcM"], "gold": []}, {"generated": ["50 \u03bcL", "10 min", "\u221280 \u00b0C", "16,000\u00d7 g"], "gold": []}, {"generated": ["0.67", "8", "0.33", "24", "0.17", "2", "1.5", "48", "4"], "gold": []}, {"generated": ["1-week"], "gold": []}, {"generated": ["0 to 48 h"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u00b11 day"], "gold": []}, {"generated": ["24 subjects"], "gold": []}, {"generated": ["malondialdehyde (MDA)"], "gold": []}, {"generated": ["disease of antioxidant deficiency"], "gold": []}, {"generated": ["markedly"], "gold": []}, {"generated": ["OS"], "gold": []}, {"generated": ["C. sinensis"], "gold": []}, {"generated": ["4 \u00b0C", "200 \u00b5L", "4 h", "1 mL", "120 g"], "gold": []}, {"generated": ["1,1\u2032,3,3\u2032-tetramethoxypropane", "0.54\u20131,32 pg/mL"], "gold": []}, {"generated": ["described"], "gold": []}, {"generated": ["25", "75"], "gold": []}, {"generated": ["group 3", "group 1", "group 2"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["FBS level", "pancreatic \u03b2 cells"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["glucose levels", "significant reduction", "insulin tolerance"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["proliferative and secretory phases", "longer follow-up"], "gold": []}, {"generated": ["patients"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["2006", "20"], "gold": []}, {"generated": ["V05895B"], "gold": []}, {"generated": ["days 0, 14, and 28"], "gold": []}, {"generated": ["treatment", "natural log transformed", "confidence intervals", "analysis of variance model"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["<50 copies/ml"], "gold": []}, {"generated": ["Darunavir"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["antiretroviral agents", "clinical pharmacokinetic interactions", "botanicals"], "gold": []}, {"generated": ["darunavir pharmacokinetics", "variability"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no relevant effect on the in vivo activity of the major CYP enzymes in humans"], "gold": []}, {"generated": ["variety of disorders"], "gold": []}, {"generated": ["8 days"], "gold": []}, {"generated": ["5-OH-OME", "OME", "internal standard", "precipitation", "DOR", "DEX", "MID assays"], "gold": []}, {"generated": ["standard bioequivalence approach"], "gold": []}, {"generated": ["120"], "gold": []}, {"generated": ["1 week", "240-mg EGb 761\u00ae daily dose"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["8-day period"], "gold": []}, {"generated": ["pharmacokinetic (PK)", "randomized controlled trials", "pharmacodynamic (PD)"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["standard eligibility inclusion criteria"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["26", "24", "28", "29", "21"], "gold": []}, {"generated": ["high risk of bias", "unclear risk of bias", "minimum age", "minus (-) marked circle"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["different ages found in text"], "gold": []}, {"generated": ["potential herb-warfarin interaction"], "gold": []}, {"generated": ["multiple reasons"], "gold": []}, {"generated": ["in vivo study", "drugs metabolized by CYP2C9"], "gold": []}, {"generated": ["in vivo study", "hepatic damage", "dose-dependent manner", "48"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["detected in her blood serum analysis", "no history of warfarin use"], "gold": []}, {"generated": ["more than 37 seconds", "more than 70 seconds", "greater than seven"], "gold": []}, {"generated": ["unknown DIC", "unknown origin", "unknown vitamin K malabsorption", "unknown coagulopathy", "unknown pathologic inhibitors"], "gold": []}, {"generated": ["study protocol", "subject enrollment"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["in vitro inhibitory potency", "human pharmacokinetic data", "well\u2010characterized composition"], "gold": []}, {"generated": ["alternate study designs", "multiple dosing", "silibinin predosing", "raloxifene"], "gold": []}, {"generated": ["oxidative metabolism", "conjugative metabolism"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["95%"], "gold": []}, {"generated": ["12-hour", "8-hour", "3-hour", "4-hour", "6-hour", "10-hour"], "gold": []}, {"generated": ["curcumin"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["comprehensive systematic review", "existing literature"], "gold": []}, {"generated": ["2012"], "gold": []}, {"generated": ["2012"], "gold": []}, {"generated": ["human", "rabbits"], "gold": []}, {"generated": ["rats", "two children"], "gold": []}, {"generated": ["long-term basis"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["reduced the plasma level of CBZ"], "gold": []}, {"generated": ["Caution"], "gold": []}, {"generated": ["patients with major depression or bipolar disorder"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["proactive monitoring"], "gold": []}, {"generated": ["significant relationship", "variables", "p < 0.05"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["that age group", "highest number of patients with type-2 diabetes"], "gold": []}, {"generated": ["hypoglycaemic agents", "pharmacological management", "Tabular summary", "patients"], "gold": []}, {"generated": ["12 identified plants"], "gold": []}, {"generated": ["patients with diabetes"], "gold": []}, {"generated": [], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["thousands of years"], "gold": []}, {"generated": ["hepatocellular carcinoma"], "gold": []}, {"generated": ["15 min"], "gold": []}, {"generated": ["22 compounds"], "gold": []}, {"generated": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "gold": []}, {"generated": ["human"], "gold": []}, {"generated": ["LTQ-Orbitrap Elite mass spectrometer", "UPLC-MS/MS analysis", "Ultimate 3000 UPLC system", "notoginsenoside R"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2 \u00d7 10 Total RNA"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["whole experiments"], "gold": []}, {"generated": ["p < 0.01", "p < 0.001"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["drug transporters", "cytochrome P450 enzymes", "CYPs"], "gold": []}, {"generated": ["human P-glycoprotein (P-gp)", "L-MDR1 cells"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["minor effect"], "gold": []}, {"generated": ["in vitro"], "gold": []}, {"generated": ["concomitantly used drugs"], "gold": []}, {"generated": ["MDCKII-BCRP cells", "parental cell line MDCKII"], "gold": []}, {"generated": ["published previously", "positively controls"], "gold": []}, {"generated": ["Banderol", "1%", "Samento"], "gold": []}, {"generated": ["miniprep Kit", "RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit"], "gold": []}, {"generated": ["previous"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Reporter gene assays"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["four days"], "gold": []}, {"generated": ["LS180 cells"], "gold": []}, {"generated": ["t = 0"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["original formulation"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2 weeks"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["throughout the study"], "gold": []}, {"generated": ["500\u00b0C", "5500 V"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["0,\u221e"], "gold": []}, {"generated": ["90% confidence intervals"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["different types of statins"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["69.90%", "65.38%"], "gold": []}, {"generated": ["Figure 5A,B"], "gold": []}, {"generated": ["66.77%", "41.06%"], "gold": []}, {"generated": ["pharmacokinetic disposition"], "gold": []}, {"generated": ["determine", "pharmacokinetic interaction", "DAS"], "gold": []}, {"generated": ["DAS 25 mg/kg"], "gold": []}, {"generated": ["12-h", "12 h", "one week"], "gold": []}, {"generated": ["Group II", "25 mg/kg", "Group I", "7 days"], "gold": []}, {"generated": ["2 hours", "40 mg/kg", "7 days", "7th day"], "gold": []}, {"generated": ["electrospray ionization", "positive direction"], "gold": []}, {"generated": ["in vivo studies", "humans"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["KSU-SE-21-58"], "gold": []}, {"generated": ["subject age", "sample age", "age group", "average age", "standard deviation", "mean age", "age range", "patient age"], "gold": []}, {"generated": ["rats", "DAS administration", "APG pretreatment"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["herb-mediated changes", "population"], "gold": []}, {"generated": ["elderly"], "gold": []}, {"generated": ["adult women"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["27", "26"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["\u221280 \u00b0C"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["height, weight, or BMI at baseline"], "gold": []}, {"generated": ["12 weeks", "baseline"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["about 20 years ago"], "gold": []}, {"generated": ["pregnane-X-receptor"], "gold": []}, {"generated": ["2004", "2012", "2019", "2017", "2006", "2009"], "gold": []}, {"generated": ["potentially relevant targets for depression"], "gold": []}, {"generated": ["time of immobility"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2018", "2019", "recently"], "gold": []}, {"generated": ["seven test drugs", "low\u2010hyperforin"], "gold": []}, {"generated": ["high quality clinical data", "cancer therapies"], "gold": []}, {"generated": ["Lingzhi", "Yunzhi"], "gold": []}, {"generated": ["significant dosage differences"], "gold": []}, {"generated": ["Figure 1"], "gold": []}, {"generated": ["83", "145", "63", "141", "111", "103", "144", "101", "84", "20", "99", "67", "98", "105"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["reactive oxygen species production", "tumor cell angiogenesis"], "gold": []}, {"generated": ["recent study", "tumor metabolism", "gut dysbiosis induced by paclitaxel"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["Multiple ages not specified"], "gold": []}, {"generated": ["clinical settings", "chemotherapeutic drugs", "adverse effects"], "gold": []}, {"generated": ["Table S4"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["described ages found in text"], "gold": []}, {"generated": ["conventional cancer therapy", "frequently"], "gold": []}, {"generated": ["70\u201380%"], "gold": []}, {"generated": ["breast cancer patients", "other types of cancer"], "gold": []}, {"generated": ["306\u2009ng/mL", "5\u2009mg"], "gold": []}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "human liver microsomes", "dextrorphan-d", "\u03b2-estradiol", "HLMs"], "gold": []}, {"generated": ["concentration-dependent inhibition of proliferation"], "gold": []}, {"generated": ["patients", "enzyme phenotypes", "metabolizers"], "gold": []}, {"generated": ["long-term outcomes", "studies"], "gold": []}, {"generated": ["50 donors"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["10", "5", "1", "2", "0.1", "100"], "gold": []}, {"generated": ["Springer Nature"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["30 min", "180 \u00b5L", "5% ammonia", "2-4-dibromoacetophenone", "520 ppm", "30 seconds"], "gold": []}, {"generated": ["4.5 mg/200 g BW", "morning", "single", "two weeks"], "gold": []}, {"generated": ["anaesthetized"], "gold": []}, {"generated": ["1.0 mL"], "gold": []}, {"generated": ["within-run accuracy", "precision", "captopril analysis"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["plasma sulfhydryl groups", "2-4-dibromoacetophenone", "captopril"], "gold": []}, {"generated": ["basic pH"], "gold": []}, {"generated": ["17"], "gold": []}, {"generated": ["expression of the PEPT1 transporter", "GSH level", "Two weeks", "H. sabdariffa extract", "coadministration"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["2016"], "gold": []}, {"generated": ["laboratory rodent"], "gold": []}, {"generated": ["Agilent 1290 series"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["might occur"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [""], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["anti-diabetic"], "gold": []}, {"generated": ["during the course of his treatment", "probably"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["seven days"], "gold": []}, {"generated": ["filtered", "previous filtrate"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["adolescents", "elderly"], "gold": []}, {"generated": ["0.642min", "0.482min"], "gold": []}, {"generated": ["inflammatory response", "diabetes", "liver damage", "oxidative stress"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["significantly different from normal group", "diabetic control group"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["9"], "gold": []}, {"generated": ["significantly different from normal group", "diabetic control group"], "gold": []}, {"generated": ["significant alterations"], "gold": []}, {"generated": ["rats"], "gold": []}, {"generated": ["plasma sample preparation", "tissue homogenates"], "gold": []}, {"generated": ["six rats"], "gold": []}, {"generated": ["4\u20135 h", "2\u20133 h", "6\u20137 h", "3\u20134 h", "5\u20136 h", "1\u20132 h", "0\u20131 h"], "gold": []}, {"generated": ["6\u201318 h", "18\u201328 h", "0\u20136 h"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["indomethacin-induced gastric injury"], "gold": []}, {"generated": ["model group", "S-AOE", "indomethacin", "M-AOE", "plasma concentration-time curves"], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": ["1.875", "1.7", "2.5"], "gold": []}, {"generated": ["occasionally", "moderate intake", "375 ml"], "gold": []}, {"generated": ["no ages found"], "gold": []}, {"generated": ["daily diet"], "gold": []}, {"generated": ["10%"], "gold": []}, {"generated": ["three patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["dose dependent manner"], "gold": []}, {"generated": ["high relative quantities"], "gold": []}, {"generated": ["44, 45"], "gold": []}, {"generated": ["7.2"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["15 day"], "gold": []}, {"generated": ["most studies"], "gold": []}, {"generated": ["hypotensive activity", "ACE inhibition", "reduction of myocardial mass", "PI3-K/Akt pathway", "ERK pathway", "blood viscosity", "anthocyanins", "new vessel formation", "calcium influx", "active site", "adipocyte differentiation", "cyclooxygenase inhibitory activity", "endothelium-derived relaxant pathways", "several potential mechanisms"], "gold": []}, {"generated": ["extremely high doses", "lower doses"], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["customers", "early version"], "gold": []}, {"generated": ["clinical importance"], "gold": []}, {"generated": ["clinically-relevant dose", "three-fold increase"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["21"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["senior citizens", "adolescents", "elderly"], "gold": []}, {"generated": ["potential mechanism\u2010based inhibitors", "in vitro", "human liver microsomes (HLM)"], "gold": []}, {"generated": ["cooling block", "Selleckchem, Houston, TX, USA"], "gold": []}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": []}, {"generated": ["clinical setting"], "gold": []}, {"generated": ["different tissues"], "gold": []}, {"generated": ["tissue-to-plasma partition coefficients"], "gold": []}, {"generated": ["three lignans"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["age"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["72"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["different cancer cell lines"], "gold": []}, {"generated": ["haemorrhage"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Real Time-Polymerase Chain Reaction", "Western blot"], "gold": []}, {"generated": ["pharmacodynamic analysis"], "gold": []}, {"generated": ["2005"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["5 min", "30 min", "12 min", "10 min", "13 min", "90 min"], "gold": []}, {"generated": ["420%"], "gold": []}, {"generated": ["mRNA expression level of CYP2C6", "doses of Danshen", "vehicle control group"], "gold": []}, {"generated": ["P < 0.001", "P < 0.05", "P < 0.01"], "gold": []}, {"generated": ["32", "24"], "gold": []}, {"generated": ["rats", "previous study"], "gold": []}, {"generated": ["taken together with the results of the current study"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["rats", "several different species", "human"], "gold": []}, {"generated": ["warfarin dose"], "gold": []}, {"generated": ["57"], "gold": []}, {"generated": ["warfarin hydroxylation"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["in vitro", "in vivo"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["early stage breast cancer"], "gold": []}, {"generated": ["publication"], "gold": []}, {"generated": ["mean recovery", "88%"], "gold": []}, {"generated": ["interference with drug quantitation", "extracted ion chromatograms"], "gold": []}, {"generated": ["37 months", "4 months", "113 months"], "gold": []}, {"generated": ["Competing interests"], "gold": []}, {"generated": ["chronically ill patients", "patients with terminal diseases"], "gold": []}, {"generated": ["asthma", "hypertension", "minor ailments", "antimicrobials", "antimalarials", "diabetes", "peptic ulcer", "chronic diseases", "cancer"], "gold": []}, {"generated": ["over 70%"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": []}, {"generated": ["Germany", "Darmstadt", "LiChrosolv GG", "Merck"], "gold": []}, {"generated": ["2013", "2005", "2007"], "gold": []}, {"generated": ["Multiple reaction monitoring (MRM) mode", "positive ion mode"], "gold": []}, {"generated": ["Fifty percent inhibitory concentration", "concentration of aqueous extract of herb"], "gold": []}, {"generated": ["commonly used herbs"], "gold": []}, {"generated": ["three of the plants", "highest dose of the extract", "eight major human CYP isoenzymes"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["oven\u2010dried Allium sativum bulbs"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Strandell"], "gold": []}, {"generated": ["2000"], "gold": []}, {"generated": ["CYP2C19", "CYP3A4", "CYP1A2"], "gold": []}, {"generated": ["menopause"], "gold": []}, {"generated": ["transition to menopause", "sleep disturbances", "weight gain", "night sweats", "sexual dysfunction", "mood disorders", "hot flashes", "cognitive declines", "problematic symptoms"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["no ages mentioned"], "gold": []}, {"generated": ["30 days"], "gold": []}, {"generated": ["851", "14 days"], "gold": []}, {"generated": ["sequentially numbered"], "gold": []}, {"generated": ["simvastatin", "Figure 4", "internal standard", "simvastatin hydroxy acid", "mean (SD)", "plasma concentrations", "lovastatin"], "gold": []}, {"generated": ["mean (SD)"], "gold": []}, {"generated": ["P < 0.05"], "gold": []}, {"generated": ["40 mg"], "gold": []}, {"generated": ["worldwide popularity"], "gold": []}, {"generated": ["65-year-old"], "gold": ["65-year-old"]}, {"generated": ["illnesses"], "gold": []}, {"generated": ["possible interactions", "lifestyle", "measures"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["All subjects"], "gold": []}, {"generated": ["2 weeks", "n= 12"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["previous studies"], "gold": []}, {"generated": ["health care professionals", "earlier surveys", "high levels of herb-drug use"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["potential", "herb-drug interactions", "first stage", "In vitro"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["type 1"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Waters Alliance 2690 HPLC", "Waters Micromass Ltd.", "HPLC conditions", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS"], "gold": []}, {"generated": ["15"], "gold": []}, {"generated": ["35"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["significantly (p \u2264 0.05)"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["ages found in text"], "gold": []}, {"generated": ["Five days"], "gold": []}, {"generated": ["well-studied treatment"], "gold": []}, {"generated": ["refractory", "extract"], "gold": []}, {"generated": ["selected single herbs", "Wen Bing formulas"], "gold": []}, {"generated": ["1902"], "gold": []}, {"generated": ["as internal standard"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["8 mg/mL", "5 \u03bcL", "600 \u03bcL"], "gold": []}, {"generated": ["30 minutes", "Day 5", "8 PM"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["all the herb/herbal components", "significantly suppressed"], "gold": []}, {"generated": ["ten marker components", "teen"], "gold": []}, {"generated": ["in-vitro experiments", "anti-influenza herbs/herbal components"], "gold": []}, {"generated": ["significantly increase", "decrease"], "gold": []}, {"generated": ["OS ratio", "oxidative stress", "rat urine samples", "OSA", "AGE", "Renal senescence", "AGEs"], "gold": []}, {"generated": ["S8"], "gold": []}, {"generated": ["influenza viruses"], "gold": []}, {"generated": ["100 \u03bcg/mL", "rat plasma", "500 \u03bcg/mL"], "gold": []}, {"generated": ["rat plasma"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["absorption rate (k", "62%", "six-dimension in-vitro screening", "in-vivo pharmacokinetics in rats", "Table 1", "ex-vivo pharmacodynamic evaluation", "after co-administration", "pop-PK model", "metabolic clearance (CL"], "gold": []}, {"generated": ["Root of Isatis indigotica Fort., Banlangen"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["pre-clinical studies"], "gold": []}, {"generated": ["breast cancer patients", "all the cancer patients"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["recent study", "MCF7", "TAM", "T47D"], "gold": []}, {"generated": ["MCF-7", "T-47D"], "gold": []}, {"generated": ["many European countries"], "gold": []}, {"generated": ["10 Evn-50", "2012"], "gold": []}, {"generated": ["12 traditional herbs"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["2015"], "gold": []}, {"generated": ["significant increase", "antioxidant enzymes", "TBARS", "rats", "TAM-intoxicated liver injury", "sGOT", "liver transaminases", "glutathione", "sGPT"], "gold": []}, {"generated": ["2009"], "gold": []}, {"generated": ["HDI", "in vitro", "BCRP", "OAT1/3", "PCA", "GA", "MDR1"], "gold": []}, {"generated": ["2000\u20132019"], "gold": []}, {"generated": ["prostatitis", "urinary tract infections", "pyelonephritis"], "gold": []}, {"generated": ["tissue distribution-based HDIs", "pharmacokinetic-based HDIs", "PCA", "GA", "PCE"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["1990", "2006", "2007", "2012"], "gold": []}, {"generated": ["14\u201315 min", "0\u20138.5 min", "11.5\u201313.5 min", "8.7\u201311 min"], "gold": []}, {"generated": ["quantification"], "gold": []}, {"generated": ["362.2", "318.1", "288.1", "332.1"], "gold": []}, {"generated": ["co-administration of CIP and PCE", "PK changes of GA and PCA", "Figures 3, 4"], "gold": []}, {"generated": ["intravenous administration", "intragastric administration"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["approximately 1%", "approximately 10%"], "gold": []}, {"generated": ["2021ZD030", "2018ZX09734-002", "2021ZD017"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["laboratory", "similar"], "gold": []}, {"generated": ["extremely", "not at all"], "gold": []}, {"generated": ["13.3", "15.00"], "gold": []}, {"generated": ["exercise time (Figure 3)", "Total Energy Expenditure (TEE)", "treatment (YM vs. PLC)"], "gold": []}, {"generated": ["24% increase", "low to moderate exercise intensities"], "gold": []}, {"generated": ["12 weeks"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["bioavailability", "active ingredients"], "gold": []}, {"generated": ["mood state", "favorable psychomotor effects", "satiety"], "gold": []}, {"generated": ["future research", "lower BF% percentile", "physically active", "longitudinal YM effectiveness"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["Seoul, Korea"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["ad libitum"], "gold": []}, {"generated": ["Rats"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["various patient demographics"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["CYP450 family", "DMEs"], "gold": []}, {"generated": ["further", "clinical", "anecdotal"], "gold": []}, {"generated": ["general well-being", "anxiety and mood disorders", "cardiovascular disorders", "fatigue", "clinically significant improvement", "symptoms of cognition decline", "memory loss"], "gold": []}, {"generated": ["subtherapeutic"], "gold": []}, {"generated": ["midazolam", "human studies"], "gold": []}, {"generated": ["itself", "chronic use"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["described entities"], "gold": []}, {"generated": ["18"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["21"], "gold": []}, {"generated": ["herbal products"], "gold": []}, {"generated": ["many marketed herbal products", "different herbal species"], "gold": []}, {"generated": ["human small intestinal enterocytes"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["drugs", "natural bioactive compounds", "rich sources"], "gold": []}, {"generated": ["kidney transplantation"], "gold": []}, {"generated": ["age found in text"], "gold": []}, {"generated": ["April 2016"], "gold": []}, {"generated": ["74.27"], "gold": []}, {"generated": ["serious adverse effects"], "gold": []}, {"generated": ["List of ages found in text"], "gold": []}, {"generated": ["graft rejection"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": [""], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": ["74.27"], "gold": []}, {"generated": ["possible effect"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["mean \u00b1 S. D.", "n = 6"], "gold": []}, {"generated": ["groups 1 and 2", "statistically significant differences", "groups 2 and 3"], "gold": []}, {"generated": ["Zuccotti Park"], "gold": []}, {"generated": ["pretreatment period", "possible herbal drug effect"], "gold": []}, {"generated": ["dryness", "evaporated", "combined"], "gold": []}, {"generated": ["elderly", "patients", "available", "senior citizens"], "gold": []}, {"generated": ["regulatory environment", "practical effects", "Europe"], "gold": []}, {"generated": ["less knowledge"], "gold": []}, {"generated": ["years"], "gold": []}, {"generated": ["most frequently occurring species"], "gold": []}, {"generated": ["56.6%"], "gold": []}, {"generated": ["described in text"], "gold": []}, {"generated": ["two studies"], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["safe daily dose"], "gold": []}, {"generated": ["short-term", "time until surgical intervention"], "gold": []}, {"generated": ["500 mg", "2\u20133 days"], "gold": []}, {"generated": ["insufficiently defined product quality"], "gold": []}, {"generated": ["emerging"], "gold": []}, {"generated": ["older adults", "teenagers"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["154"], "gold": []}, {"generated": [], "gold": []}, {"generated": [], "gold": []}, {"generated": [""], "gold": []}, {"generated": ["not specified"], "gold": []}, {"generated": ["2018"], "gold": []}, {"generated": ["more frequently", "these groups"], "gold": []}, {"generated": ["3 weeks"], "gold": []}, {"generated": ["unusually susceptible", "individual genotype"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["human"], "gold": []}, {"generated": ["weekly", "28%", "7.5", "15"], "gold": []}, {"generated": ["individual susceptibility"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["great proportion"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["institutional affiliations", "published maps"], "gold": []}, {"generated": ["variety of ages found in text"], "gold": []}, {"generated": ["not applicable"], "gold": []}, {"generated": ["HDI", "pharmacodynamic"], "gold": []}, {"generated": ["large number of sulfur compounds", "bioactive compounds", "allyl thiosulfinates (mainly allicin)", "allyl thiosulfinates"], "gold": []}, {"generated": ["two millennia"], "gold": []}, {"generated": ["individuals with diabetes"], "gold": []}, {"generated": ["experimental"], "gold": []}, {"generated": ["conventional antidiabetics"], "gold": []}, {"generated": ["98"], "gold": []}, {"generated": ["more complex interactions", "complex herbal interventions", "relevant chemical and pharmacological data"], "gold": []}, {"generated": ["no ages found in text"], "gold": []}, {"generated": ["Springer Nature"], "gold": []}, {"generated": ["various ages found in text"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["several studies"], "gold": []}, {"generated": ["USP reference standard"], "gold": []}, {"generated": ["HPLC determinations", "General-purpose reagents", "HPLC grade solvents"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["significant P value \u2a7d0.05"], "gold": []}, {"generated": ["concentration dependent manner", "in vitro"], "gold": []}, {"generated": ["25 \u03bcg/ml"], "gold": []}, {"generated": ["healthy human volunteers"], "gold": []}, {"generated": ["clinical study"], "gold": []}, {"generated": [], "gold": []}, {"generated": ["abemaciclib-related diarrhea", "quality of life", "patients' outcomes"], "gold": []}, {"generated": [], "gold": []}]}